title: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
abstract: Adoptive cell therapy (ACT) with tumor-reactive lymphocytes in patients with refractory melanoma can result in tumor regression and prolonged survival. Generating tumor-reactive lymphocyte cultures is technically difficult and resource intensive; these limitations have restricted the widespread application of ACT. Tumor-infiltrating lymphocytes (TIL) from melanoma contain tumor antigen-reactive cells. The "standard" method for producing TIL cultures for clinical administration requires extended in vitro expansion in interleukin-2, then identification of tumor-reactive cells by immunologic assays. We show here that limitations in reagents and methods during screening underrepresent the actual reactivity of TIL cultures. Furthermore, the extended culture times necessitated by the screening assays resulted in telomere shortening and reduced expression of CD27 and CD28 in the TIL cultures, properties that our prior studies showed are correlated with in vivo persistence and clinical response. We have thus developed an alternative "young" TIL method that demonstrated superior in vitro attributes compared with standard TIL. This approach uses the entire resected tumor to rapidly expand TIL for administration without in vitro testing for tumor recognition. Our observations suggest that younger TIL can have an undetermined but high level of antigen reactivity, and other advantageous attributes such as long telomeres and high levels of CD27 and CD28. We suggest that minimally cultured, unselected lymphocytes represent an alternative strategy for generating TIL cultures suitable for use in ACT that, if effective in vivo, may facilitate the widespread application of this approach to a broader population of patients with melanoma.
authors.affiliation: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
authors.forename: Khoi Q
authors.initials: KQ
authors.lastname: Tran
authors.forename: Juhua
authors.initials: J
authors.lastname: Zhou
authors.forename: Katherine H
authors.initials: KH
authors.lastname: Durflinger
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Langhan
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Shelton
authors.forename: John R
authors.initials: JR
authors.lastname: Wunderlich
authors.forename: Paul F
authors.initials: PF
authors.lastname: Robbins
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: Mark E
authors.initials: ME
authors.lastname: Dudley
mesh_terms: D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D016207:Cytokines / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000637:transplantation*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D016615:Telomere / Q000502:physiology
chemical_list: D016207:Cytokines
references.citation: J Immunol Methods. 1990 Apr 17;128(2):189-201
references.pmid: 1691237
references.citation: J Immunother. 2005 May-Jun;28(3):258-67
references.pmid: 15838383
references.citation: J Immunother (1991). 1992 Jul;12(1):1-12
references.pmid: 1637779
references.citation: J Immunol. 2005 Nov 15;175(10):7046-52
references.pmid: 16272366
references.citation: J Immunol. 2006 Nov 1;177(9):6527-39
references.pmid: 17056585
references.citation: Cancer. 2007 Feb 1;109(3):455-64
references.pmid: 17200963
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
references.pmid: 12427970
references.citation: J Immunol. 2006 Jun 15;176(12):7726-35
references.pmid: 16751420
references.citation: Blood. 2005 Jan 1;105(1):241-50
references.pmid: 15345595
references.citation: Science. 2006 Oct 6;314(5796):126-9
references.pmid: 16946036
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
references.pmid: 15980149
references.citation: Int J Cancer. 2007 Jan 15;120(2):337-43
references.pmid: 17066423
references.citation: J Clin Invest. 2005 Jun;115(6):1616-26
references.pmid: 15931392
references.citation: Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4
references.pmid: 10685652
references.citation: Science. 2002 Oct 25;298(5594):850-4
references.pmid: 12242449
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2346-57
references.pmid: 15800326
references.citation: N Engl J Med. 1988 Dec 22;319(25):1676-80
references.pmid: 3264384
references.citation: Blood. 1998 Sep 1;92(5):1549-55
references.pmid: 9716582
references.citation: J Immunother. 2007 Jan;30(1):123-9
references.pmid: 17198091
references.citation: J Immunother. 2003 Jul-Aug;26(4):332-42
references.pmid: 12843795
references.citation: J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66
references.pmid: 8028037
references.citation: Science. 2003 Apr 11;300(5617):339-42
references.pmid: 12690202
references.citation: J Immunother. 2002 May-Jun;25(3):243-51
references.pmid: 12000866
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5060-9
references.pmid: 17075125
references.citation: Blood. 2007 Aug 15;110(4):1123-31
references.pmid: 17468341
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613
references.citation: Immunol Rev. 1997 Jun;157:195-216
references.pmid: 9255631
references.citation: Science. 2003 Apr 11;300(5617):337-9
references.pmid: 12690201
references.citation: Blood. 2005 Mar 1;105(5):1898-904
references.pmid: 15542583